Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
ConditionDyslipidemias
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorNewAmsterdam Pharma
About this trial
The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab
Patients will:
Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg/dL obicetrapib daily/evolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16
Eligibility criteria
Qualifiers
Lp(a): >=50 mg/dL (>=125 nmol/L) for cohort 1 (FILLED) and Lp(a) >= 20 mg/dL (>= 50 nmol/L) to <50 mg/dL (< 125 nmol/L) for cohort 2
LDL-C >70 mg/dL
TG < 400mg/dL (<4.52 mmol/L)
Disqualifiers
HbA1c>=10 or FPG >=270 mg/dL
CV events within 3 months of screen
Trial design
Treatments tested in this trial
- obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
Treatment groups
69 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov